Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Chicago, IL
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Topeka, KA
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Baltimore, MD
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Boston, MA
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Detroit, MI
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Duluth, MN
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Duluth, MN
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Tupelo, MS
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Tupelo, MS
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Billings, MT
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Butte, MT
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Butte, MT
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Sommers Point, NJ
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Sommers Point, NJ
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Rochester, NY
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Akron, OH
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Columbus, OH
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Lima, OH
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Lima, OH
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Rapid City, SD
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated:  12/18/2015
mi
from
Hamilton,
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Status: Enrolling
Updated: 12/18/2015
mi
from
Hamilton,
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
San Diego, CA
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Walnut Creek, CA
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
DeLand, FL
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Miami, FL
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Miami, FL
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Newton, KA
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Newton, KA
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Bardstown, KY
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Kansas City, MO
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Rochester, NY
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Cary, NC
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Cary, NC
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Akron, OH
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Cleveland, OH
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
New Braunfels, TX
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
New Braunfels, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  12/18/2015
Clinical Research Facility
mi
from
South Jordan, UT
A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 12/18/2015
Clinical Research Facility
mi
from
South Jordan, UT
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Orange, CA
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
San Diego, CA
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Bronx, NY
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Akron, OH
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Houston, TX
Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Behavioral Interventions for Control of TB
Behavioral Interventions for Control of Tuberculosis
Status: Enrolling
Updated:  12/21/2015
Columbia University
mi
from
New York, NY
Behavioral Interventions for Control of TB
Behavioral Interventions for Control of Tuberculosis
Status: Enrolling
Updated: 12/21/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Exhaled Nitric Oxide Levels in Infants and Young Children Infected With RSV or Other Viral Infections
A Prospective Study Measuring Exhaled Nitric Oxide Levels in Infants and Young Children Admitted to the Hospital for Respiratory Syncytial Virus (RSV) or Other Viral Lower Respiratory Tract Infections
Status: Enrolling
Updated:  12/23/2015
Winthrop University Hospital
mi
from
Mineola, NY
Exhaled Nitric Oxide Levels in Infants and Young Children Infected With RSV or Other Viral Infections
A Prospective Study Measuring Exhaled Nitric Oxide Levels in Infants and Young Children Admitted to the Hospital for Respiratory Syncytial Virus (RSV) or Other Viral Lower Respiratory Tract Infections
Status: Enrolling
Updated: 12/23/2015
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Residual Sample Collection for Respiratory Viral Panel
De-identified Residual Sample Collection for the Respiratory Viral Panel on the GenMark Sample to Answer Platform (ARM 1)
Status: Enrolling
Updated:  12/23/2015
Penn State Hershey Medical Center
mi
from
Hershey, PA
Residual Sample Collection for Respiratory Viral Panel
De-identified Residual Sample Collection for the Respiratory Viral Panel on the GenMark Sample to Answer Platform (ARM 1)
Status: Enrolling
Updated: 12/23/2015
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials